002581 Shandong Sinobioway Biomedicine
- 8.24
- +0.05+0.61%
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceuticals: 2024 Semi-Annual Report Summary
Unnamed Pharmaceuticals: Announcement on Cancelling Some Stock Options of the 2023 Stock Options Incentive Plan and Adjusting the List of Incentive Targets
Unnamed Pharmaceuticals: Half-year summary table of non-operating capital usage and other related capital transactions
Unnamed Pharmaceuticals: 2024 Semi-Annual Financial Report
Unnamed Medicine: Resolutions of the 3rd Special Meeting of Independent Directors of the 5th Board of Directors
Unnamed Pharmaceuticals: Semi-Annual Report Board Resolution Announcement
Unknown medicine: inspection opinions of the board of supervisors on matters related to the 17th meeting of the 5th board of supervisors of the company
Unnamed Pharmaceuticals: Announcement on the Appointment of a Secretary of the Board
Unnamed Pharmaceuticals: Supplementary Announcement on the Achievement of the Enforcement Conditions for the First Exercise Period of the 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Announcement of Resolutions of the Supervisory Board in the Semi-Annual Report
Unnamed Pharmaceuticals: Announcement on the Resignation of the Company\'s Board Secretary
Unnamed Pharmaceuticals: Semi-Annual Report 2024
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on Shandong Weiming Biomedical Co., Ltd. canceling some stock options and adjusting the list of incentive recipients in the 2023 Stock Option Incentive Plan
Shandong Sinobioway Biomedicine: Announcement regarding receipt of Administrative Penalty Decision from China Securities Regulatory Commission.
Shandong Sinobioway Biomedicine: Announcement on the Progress of Completing the Internal Transfer of Equity and Business Registration Changes of Subsidiaries.
Shandong Sinobioway Biomedicine: Regulations on Public Opinion Management (July 2024)
Shandong Sinobioway Biomedicine: Announcement regarding the proposed transfer of equity in a subsidiary company via public listing.
Shandong Sinobioway Biomedicine: Report on the valuation of all equity values of shareholders involved in the equity transfer of Yingkou Yingxin Chemical Technology Co., Ltd.
Shandong Sinobioway Biomedicine: Announcement of Resolution of the 25th Meeting of the Board of Directors of the 5th Session.
Shandong Sinobioway Biomedicine: On the financial statements and related notes after accounting errors correction in the previous period.
Analysis
Price Target
No Data
